Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.

[1]  K. Kohno,et al.  Possible involvement of multidrug‐resistance‐associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells , 1994, International journal of cancer.

[2]  A. Fojo,et al.  Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. , 1994, The Journal of biological chemistry.

[3]  S. Aaronson,et al.  Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. , 1994, Cancer research.

[4]  M. Barrand,et al.  A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. , 1994, Journal of the National Cancer Institute.

[5]  D. Hipfner,et al.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.

[6]  M. Center,et al.  The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. , 1993, Cancer research.

[7]  M. Slovak,et al.  Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. , 1993, Cancer research.

[8]  F. Baas,et al.  Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. , 1993, Cancer research.

[9]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[10]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[11]  M. Kuwano,et al.  Polyoma middle T antigen or v-src desensitizes human epidermal growth factor receptor function and interference by a monensin-resistant mutation in mouse Balb/3T3 cells. , 1992, Experimental cell research.

[12]  H. Takano,et al.  DNA topoisomerase-targeting antitumor agents and drug resistance. , 1992, Anti-cancer drugs.

[13]  T. Tsuruo,et al.  Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. , 1992, The Journal of urology.

[14]  D. Marquardt,et al.  Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. , 1992, Cancer research.

[15]  H. Takano,et al.  Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. , 1991, Cancer research.

[16]  H. Takano,et al.  Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. , 1990, Cancer research.

[17]  Michael J. Hartshorn,et al.  Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport , 1990, Nature.

[18]  K. Kohno,et al.  Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. , 1990, Cancer research.

[19]  H. Takano,et al.  The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. , 1989, Biochemical and biophysical research communications.

[20]  I. Pastan,et al.  Expression of Multidrug Resistance Gene in Human Cancers , 1989 .

[21]  H. Takano,et al.  Vincristine‐resistant Human Cancer KB Cell Line and Increased Expression of Multidrug‐resistance Gene , 1988, Japanese journal of cancer research : Gann.

[22]  I. Pastan,et al.  The multidrug transporter, a double-edged sword. , 1988, The Journal of biological chemistry.

[23]  V. Ling,et al.  Mechanism of multidrug resistance. , 1988, Biochimica et biophysica acta.

[24]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[25]  V. Laudone,et al.  An overview of intravesical therapy for superficial bladder tumors. , 1987, The Journal of urology.

[26]  J. Trent,et al.  Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. , 1987, Cancer research.

[27]  M. Center,et al.  Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. , 1987, Cancer research.

[28]  M. Kuwano,et al.  Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. , 1986, Cancer research.

[29]  J. Bubeník,et al.  Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen , 1973, International journal of cancer.

[30]  K. Cowan,et al.  Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. , 1994, Cancer research.

[31]  J. Kumazawa,et al.  Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. , 1992, European urology.

[32]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.